Journal: Annals of Medicine

Article Title: Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan

doi: 10.1080/07853890.2024.2442533

Figure Lengend Snippet: Neutralizing antibody levels between groups and post-vaccination days. Analysis of neutralizing antibody levels using the cPass SARS-CoV2 neutralizing antibody assay after 2 doses of vaccination. (A) Comparison of neutralizing antibody levels between 3 groups of participants who received the vaccine (1st and 2nd dose of vaccine combinations) from AstraZeneca (AZD1222) and Moderna (mRNA-1273) vaccines. (B) Longitudinal analysis of the correlation between neutralizing antibody levels and post-vaccination days who received the AZD1222 + AZD1222 vaccine group (blue color). (C). Longitudinal analysis of the correlation between neutralizing antibody levels and post-vaccination days who received the AZD1222 + mRNA-1273 vaccine group(green color). (D) Longitudinal analysis of the correlation between neutralizing antibody levels and post-vaccination days who received the mRNA-1273 + mRNA1273 vaccine group (red color). The difference in neutralizing antibody levels between groups was analyzed using the Kruskal-Wallis test (ns: not significant and **** p < 0.0001). Data were expressed as median and IQR. The Pearson correlation was used for the analysis of the correlation between neutralizing antibody levels and post-vaccination days.

Article Snippet: A study in Thailand with other mRNA vaccine boosters (Pfizer-BioNTech/BNT) also shows higher antibody levels than AZD1222 boosters in healthcare workers [ ].

Techniques: Comparison, Vaccines

Journal: Annals of Medicine

Article Title: Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan

doi: 10.1080/07853890.2024.2442533

Figure Lengend Snippet: Neutralizing antibody levels and age. Correlation of antibody levels and age, measured using cPass SARS-CoV-2 neutralizing antibody assay after 2 doses of vaccination with age: (A) AZD1222 + AZD1222 vaccine group (blue color). (B) AZD1222 + mRNA-1273 vaccine group (green color). (C) mRNA-1273 + mRNA-1273 vaccine group (red color). The Pearson correlation was used for the analysis of the correlation between neutralizing antibody levels and age.

Article Snippet: A study in Thailand with other mRNA vaccine boosters (Pfizer-BioNTech/BNT) also shows higher antibody levels than AZD1222 boosters in healthcare workers [ ].

Techniques:

Journal: BMC Infectious Diseases

Article Title: Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses — fall 2021, Wisconsin

doi: 10.1186/s12879-023-08332-7

Figure Lengend Snippet: Summary of COVID-19 vaccine types, platforms, and dosing schedules for nonimmunocompromised domestic and international students attending the University of Wisconsin - Madison, fall 2021

Article Snippet: No obvious visual differences existed in IgG level improvement associated with either Moderna or Pfizer-BioNTech mRNA vaccine boosters.

Techniques: Plasmid Preparation, Recombinant

Journal: BMC Infectious Diseases

Article Title: Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses — fall 2021, Wisconsin

doi: 10.1186/s12879-023-08332-7

Figure Lengend Snippet: Summary of serology results by primary series and booster dose status — fall academic semester 2021, Wisconsin

Article Snippet: No obvious visual differences existed in IgG level improvement associated with either Moderna or Pfizer-BioNTech mRNA vaccine boosters.

Techniques: Plasmid Preparation

Journal: BMC Infectious Diseases

Article Title: Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses — fall 2021, Wisconsin

doi: 10.1186/s12879-023-08332-7

Figure Lengend Snippet: Distribution of anti-SARS-CoV-2 IgG antibody levels from sera samples ( N = 51) collected from a sample of university students ( N = 49) with receipt of an mRNA COVID-19 vaccine booster dose — fall academic semester 2021, Wisconsin. Top row, A: antibody levels targeting the spike protein of SARS-CoV-2 (anti-S). Bottom row, B: antibody levels targeting the nucleocapsid of SARS-CoV-2 (anti-N). Within each row, on the left, a scatterplot—shaded according to previous COVID-19 status—and overlaid boxplot displays antibody levels in WHO-standardized binding antibody units per milliliter (BAU/mL), log(10) scale. On the right, notched boxplots are presented, reflecting the 95% confidence intervals around the median value; these only reflect data from students without previous COVID-19. Total datapoints per category are included above each vaccine group. Horizontal dashed lines indicate the assay threshold of positivity. One student (with receipt of Covaxin primary, J&J/Janssen booster) not presented

Article Snippet: No obvious visual differences existed in IgG level improvement associated with either Moderna or Pfizer-BioNTech mRNA vaccine boosters.

Techniques: Binding Assay

Journal: BMC Infectious Diseases

Article Title: Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses — fall 2021, Wisconsin

doi: 10.1186/s12879-023-08332-7

Figure Lengend Snippet: Anti-S IgG antibody levels and multivariate mixed-effects regression model estimates among university students with no history of COVID-19 or immunocompromised status, faceted by booster dose receipt — fall academic semester 2021, Wisconsin. Panels display levels of antibody targeting the spike protein of SARS-CoV-2 (anti-S), in WHO-standardized binding antibody units per milliliter (BAU/mL), log (10) scale. Sex-adjusted, mixed-effects linear regression estimates are superimposed on top of scatter plots with shading reflecting the 95% confidence intervals to estimate anti-S decline associated with primary series vaccine type (e.g., mRNA vs inactivated whole virus, or IWV). Panel A displays anti-S values of students with receipt of COVID-19 vaccine primary series across months since completion of primary series. Panel B displays anti-S values of students who received an mRNA booster dose across months since receipt of booster dose. Data outliers that were not included in the model based on Cook’s Distance are denoted as a boxed point and were not used to calculate adjusted regression lines

Article Snippet: No obvious visual differences existed in IgG level improvement associated with either Moderna or Pfizer-BioNTech mRNA vaccine boosters.

Techniques: Binding Assay

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Overview of study design. The main risk period was days 0-28 after receipt of a bivalent covid-19 mRNA booster as fourth dose. The total reference period consisted of ≥29 days after a third dose (up to the day before the fourth dose (ie, day 0 minus 1 day)) and the fourth dose (second booster). See supplementary figure S1 for the distribution of reference period and main risk period person time during the study period

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Characteristics of study participants vaccinated with a monovalent mRNA vaccine as a third dose and a bivalent omicron adapted vaccine as a fourth dose in Denmark. Values are number (percentage) unless stated otherwise

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques: Western Blot, Northern Blot

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by sex. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by age subgroups. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. NE=not estimable

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by type of vaccine received. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. *Corresponding number of events and person years are presented in supplementary table S3. NE=not estimable

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques:

Journal: The BMJ

Article Title: Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

doi: 10.1136/bmj-2023-075015

Figure Lengend Snippet: Risk of cerebrovascular infarction, myocarditis, and pericarditis after vaccination with a bivalent omicron adapted booster as fourth dose within 28 days in Danish adults aged ≥50 year during 15 September 2022 to 10 December 2022, including by sex, age, and vaccine type

Article Snippet: The study cohort comprised a total of 2 225 567 adults (mean age 66.9 years, standard deviation (SD) 11.0 years, and 52.0% were female participants) who had received at least three covid-19 vaccine doses (91.2% received a monovalent Pfizer-BioNTech vaccine as the third dose), of whom 1 740 417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron adapted mRNA booster vaccine from 15 September 2022 to 10 December 2022 ( and ).

Techniques: